Charles C. Wykoff, MD, PhD

Associate Professor of Clinical Ophthalmology, Academic Institute
Associate Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Biography

Charles Wykoff, MD, PhD, graduated Phi Beta Kappa from MIT, received his PhD from Oxford University in England while on a Marshall Scholarship, and his MD from Harvard Medical School. As a medical student he co-authored the book Fighting Global Blindness. While pursuing vitreoretinal training at Bascom Palmer Eye Institute he was awarded a Heed Fellowship, the Ronald G. Michels Fellowship Award, and served as Chief Resident/Co-Director of Ocular Trauma.

Dr. Wykoff has extensive expertise in clinical trial design and coordination. His research interests pertain to angiogenesis and retinal vascular diseases including age-related macular degeneration, diabetic retinopathy, and venous occlusive diseases, as well as vitreoretinal surgery topics such as retinal detachment and macular surgery. Dr. Wykoff has written and published over 120 peer-reviewed scientific manuscripts, book chapters, national meeting presentations and abstracts. Dr. Wykoff is Director of the Retina Consultants of Houston and Houston Methodist Hospital joint Argus II retinal prosthetic program – the only Gulf Coast site approved for surgical implantation of this unique technology for patients blind from retinitis pigmentosa. Dr. Wykoff is Co-Director of the Greater Houston Retina Research Foundation, was awarded the American Academy of Ophthalmology Achievement Award in 2015 and is an elected member of the Retina Society and the Macula Society. He also serves as the Academic Program Director for the Vit-buckle Society Annual Meeting, and is a member of the AAO, ARVO, ASRS and FACS.

Areas Of Expertise

Retina Diabetic retinopathy Macular degeneration Vitreoretinal surgery
Education & Training

Internship, Harvard University
MD, Harvard University
Clinical Fellowship, Bascom Palmer Eye Inst & Hosp
Residency, Bascom Palmer Eye Inst & Hosp
Publications

Thresholds for Initiating Treatment of Eyes with Diabetic Macular Edema and Good Vision: Consideration of DRCR.Net Protocol V Results
Wykoff, CC 2019, Ophthalmology Retina, vol. 3, no. 11, pp. 917-919. https://doi.org/10.1016/j.oret.2019.07.007

Distribution of Nonperfusion and Neovascularization on Ultrawide-Field Fluorescein Angiography in Proliferative Diabetic Retinopathy (RECOVERY Study): Report 1
Fan, W, Nittala, MG, Velaga, SB, Hirano, T, Wykoff, CC, Ip, M, Lampen, SIR, van Hemert, J, Fleming, A, Verhoek, M & Sadda, SVR 2019, American Journal of Ophthalmology, vol. 206, pp. 154-160. https://doi.org/10.1016/j.ajo.2019.04.023

Classification of Regions of Nonperfusion on Ultra-widefield Fluorescein Angiography in Patients with Diabetic Macular Edema
Fang, M, Fan, W, Shi, Y, Ip, MS, Wykoff, CC, Wang, K, Falavarjani, KG, Brown, DM, van Hemert, J & Sadda, SVR 2019, American Journal of Ophthalmology, vol. 206, pp. 74-81. https://doi.org/10.1016/j.ajo.2019.03.030

Office-based intravitreal injection of expansile gas for management of macular hole in previously vitrectomized eyes
Apolinario, MA, Lampen, SIR, Wong, TP, Henry, CR & Wykoff, CC 2019, American Journal of Ophthalmology Case Reports, vol. 15, 100492. https://doi.org/10.1016/j.ajoc.2019.100492

Quarterly Anti-Vascular Endothelial Growth Factor Dosing for Neovascular Age-Related Macular Degeneration: Real-World Clinical Outcomes
Rusakevich, AM, Zhou, B, Wong, TP & Wykoff, CC 2019, Ophthalmic surgery, lasers & imaging retina, vol. 50, no. 9, pp. e250-e256. https://doi.org/10.3928/23258160-20190905-17

How protocol AA fits into evolution of the diabetic retinopathy severity scale
Wykoff, CC 2019, Retina Today, vol. 2019, no. September, pp. 41-43.

Relationship Between Retinal Fractal Dimension and Nonperfusion in Diabetic Retinopathy on Ultrawide-Field Fluorescein Angiography
Fan, W, Nittala, MG, Fleming, A, Robertson, G, Uji, A, Wykoff, CC, Brown, DM, van Hemert, J, Ip, M, Wang, K, Falavarjani, KG, Singer, M, Sagong, M & Sadda, SVR 2019, American Journal of Ophthalmology. https://doi.org/10.1016/j.ajo.2019.08.015

Real-World Trends in Intravitreal Injection Practices among American Retina Specialists
Chaturvedi, R, Wannamaker, KW, Riviere, PJ, Khanani, AM, Wykoff, CC & Chao, DL 2019, Ophthalmology Retina, vol. 3, no. 8, pp. 656-662. https://doi.org/10.1016/j.oret.2019.03.023

Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes
TREX-DME Study Group 2019, American Journal of Ophthalmology, vol. 202, pp. 91-99. https://doi.org/10.1016/j.ajo.2019.02.005

Intravitreal Fluocinolone Acetonide May Decelerate Diabetic Retinal Neurodegeneration
Lynch, SK, Lee, K, Chen, Z, Folk, JC, Schmidt-Erfurth, U, Gerendas, BS, Wahle, A, Wykoff, CC & Abràmoff, MD 2019, Investigative ophthalmology & visual science, vol. 60, no. 6, pp. 2134-2139. https://doi.org/10.1167/iovs.18-24643

Re: Adrean et al.: Consistent long-term therapy of neovascular age-related macular degeneration managed by 50 or more anti-VEGF injections using a treat-extend-stop protocol (Ophthalmology. 2018;125:1047-1053)
Wykoff, CC, Rusakevich, AM & Moshfeghi, DM 2019, Ophthalmology, vol. 126, no. 3, pp. e18-e19. https://doi.org/10.1016/j.ophtha.2018.10.005

Fovea-sparing rhegmatogenous retinal detachments: impact of clinical factors including time to surgery on visual and anatomic outcomes
Lee, IT, Lampen, SIR, Wong, TP, Major, JC & Wykoff, CC 2019, Graefes Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-018-04236-4

Suprachoroidally injected pharmacological agents for the treatment of chorio-retinal diseases: a targeted approach
Habot-Wilner, Z, Noronha, G & Wykoff, CC 2019, Acta Ophthalmologica. https://doi.org/10.1111/aos.14042

Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA Study
Wykoff, CC, Shah, C, Dhoot, D, Coleman, HR, Thompson, D, Du, W, Baker, K, Vitti, R, Berliner, AJ, Metzig, C & Saroj, N 2019, Ophthalmology. https://doi.org/10.1016/j.ophtha.2019.03.040

Progression characteristics of ellipsoid zone loss in macular telangiectasia type 2
The MacTel Study Group 2019, Acta Ophthalmologica. https://doi.org/10.1111/aos.14110

Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial
Sahni, J, Patel, SS, Dugel, PU, Khanani, AM, Jhaveri, CD, Wykoff, CC, Hershberger, VS, Pauly-Evers, M, Sadikhov, S, Szczesny, P, Schwab, D, Nogoceke, E, Osborne, A, Weikert, R & Fauser, S 2019, Ophthalmology. https://doi.org/10.1016/j.ophtha.2019.03.023

Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial
RECOVERY Study Group 2019, Ophthalmology Retina. https://doi.org/10.1016/j.oret.2019.07.011

Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial
Liao, DS, Grossi, FV, El Mehdi, D, Gerber, MR, Brown, DM, Heier, JS, Wykoff, CC, Singerman, LJ, Abraham, P, Grassmann, F, Nuernberg, P, Weber, BHF, Deschatelets, P, Kim, RY, Chung, CY, Ribeiro, RM, Hamdani, M, Rosenfeld, PJ, Boyer, DS, Slakter, JS & Francois, CG 2019, Ophthalmology. https://doi.org/10.1016/j.ophtha.2019.07.011

Protecting vision in patients with diabetes with ultra-widefield imaging: A review of current literature
Singh, RP, Hsueh, J, Han, MM, Kuriyan, AE, Conti, FF, Steinle, N, Weng, CY, Wong, RW, Martinez, JA & Wykoff, CC 2019, Ophthalmic Surgery Lasers and Imaging Retina, vol. 50, no. 10, pp. 639-648. https://doi.org/10.3928/23258160-20191009-07

Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data
Sadda, SR, Campbell, J, Dugel, PU, Holekamp, NM, Kiss, S, Loewenstein, A, Augustin, AJ, Shih, V, Xu, X, Wykoff, CC & Whitcup, SM 2019, Eye (Basingstoke). https://doi.org/10.1038/s41433-019-0522-z

Live Chat Available